University of Minnesota
To provide full documentation and a comprehensive review of all aspects of pandemic influenza vaccine preparedness and response, and a blueprint for future pandemic influenza vaccine preparedness
We are winding down much of our work in biosecurity. In particular, we feel we have done our part in preparedness as well as in raising awareness of issues of potentially dangerous research in the life sciences. An effective influenza vaccine is the primary tool public health has to reduce the human illness burden caused by influenza. For more than five years, significant planning activities around pandemic vaccine production, allocation and distribution have occurred. In October we discussed the H1N1 vaccine situation internally and decided that we should support an ex post evaluation of how the U.S. has handled the H1N1 situation and see what lessons can be learned to improve responses the next time around. Shortly thereafter, we approved a $20,000 grant to Michael Osterholm and colleagues at the Center for Infectious Disease Research and Policy. A leading figure in the field of infectious diseases and public health, Michael Osterholm is the Director, Center for Infectious Disease Research and Policy; Director, Minnesota Center of Excellence for Influenza Research and Surveillance; Professor, Environmental Health Sciences, School of Public Health; and Adjunct Professor, Medical School at the University of Minnesota. Osterholm and colleagues propose a one-year project to provide a comprehensive documentation and review of all aspects of pandemic influenza vaccine preparedness and response based on the events of the current H1N1 vaccine effort and, on the basis of that documentation and review, to provide a blueprint for future pandemic influenza vaccine preparedness and identify applicable lessons for other mass vaccination campaigns. They have assembled an impressive Expert Advisory Group that includes current and former vaccine industry executives, former government officials, leaders in public health, a risk communication specialist, and influenza researchers. The strength, diversity, and commitment of this group is key because the project will require the cooperation of many different groups, including vaccine manufacturers, public health practitioners, and senior U.S. government officials. We feel that this is an important opportunity to elucidate what went wrong and what was done correctly in the current pandemic.